This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

INVICTUS study - rivaroxaban versus warfarin in rheumatic heart disease-associated atrial fibrillation (AF)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Rivaroxaban versus warfarin in Rheumatic Heart Disease-Associated Atrial Fibrillation (AF)

Connolly SJ et al invesigated whether rivaroxaban therapy would be noninferior to vitamin K antagonist therapy in patients with atrial fibrillation and echocardiographically documented rheumatic heart disease:

  • enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA2DS2VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), a mitral-valve area of no more than 2 cm2, left atrial spontaneous echo contrast, or left atrial thrombus
  • patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist
  • primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or noncardiac) or unknown causes
  • primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis

Study results:

  • of 4565 enrolled patients, 4531 were included in the final analysis
  • mean age of the patients was 50.5 years, and 72.3% were women
  • permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits
  • in the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event
  • survival curves were nonproportional
    • restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, -76 days; 95% confidence interval [CI], -121 to -31; P<0.001)
    • a higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28)
  • for the primary outcome of stroke, systemic embolism, MI, or death from vascular or unknown causes, there were 560 events in the rivaroxaban-treated patients and 446 events in those treated with a VKA (HR 1.25; 95% CI 1.10-1.41)
    • in terms of individual components of the primary endpoint, rivaroxaban increased risk of death by 23% and risk of stroke by 37%
  • no significant between-group difference in the rate of major bleeding was noted

The study authors concluded that:

  • among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.